Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Gene Mutation”

62 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 62 results

Testing effectiveness (Phase 2)Ended earlyNCT04030429
What this trial is testing

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

Who this might be right for
Endometrial Cancer Recurrent
National Cheng-Kung University Hospital 40
Large-scale testing (Phase 3)Looking for participantsNCT06988475
What this trial is testing

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Who this might be right for
Solid TumourHaematological MalignancyMalignant Neoplasm+8 more
Cancer Research UK 30
Not applicableStudy completedNCT01091506
What this trial is testing

A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients

Who this might be right for
Schizophrenia
Pamlab, Inc. 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07153770
What this trial is testing

Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

Who this might be right for
NSCLCMET Exon 14 MutationMET Activating Mutation
Shanghai Pulmonary Hospital, Shanghai, China 34
Early research (Phase 1)Ended earlyNCT05435846
What this trial is testing

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer
Collin Blakely 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Testing effectiveness (Phase 2)Looking for participantsNCT04270591
What this trial is testing

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Who this might be right for
C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd. 183
Not applicableStudy completedNCT00762268
What this trial is testing

A Trial of SAMe for Treatment-Resistant Bipolar Depression

Who this might be right for
Bipolar DisorderDepressionBipolar Depression
Mclean Hospital 23
Early research (Phase 1)Study completedNCT01531361
What this trial is testing

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Who this might be right for
Advanced Malignant NeoplasmBRAF Gene MutationMetastatic Malignant Neoplasm+2 more
M.D. Anderson Cancer Center 46
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Testing effectiveness (Phase 2)Ended earlyNCT02920996
What this trial is testing

Merestinib In Non-Small Cell Lung Cancer And Solid Tumors

Who this might be right for
Carcinoma, Non-Small-Cell LungSolid Tumor
Dana-Farber Cancer Institute 12
Testing effectiveness (Phase 2)Study completedNCT03887169
What this trial is testing

Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.

Who this might be right for
Pulmonary Alveolar ProteinosisMutation Ala393Thr of the MARS GenemutationSer567Leu of the MARS Gene
Assistance Publique - Hôpitaux de Paris 3
Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)WithdrawnNCT04460729
What this trial is testing

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Who this might be right for
Non-small Cell Lung Carcinoma (NSCLC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT01580735
What this trial is testing

ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer

Who this might be right for
Non-small-cell Lung Cancer
Kyowa Kirin Co., Ltd. 40
Testing effectiveness (Phase 2)Study completedNCT02648724
What this trial is testing

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

Who this might be right for
OncologyMET Gene AmplificationNSCLC+2 more
Symphogen A/S 57
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Testing effectiveness (Phase 2)Ended earlyNCT04926831
What this trial is testing

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 4
Not applicableStudy completedNCT03647215
What this trial is testing

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

Who this might be right for
Chronic Phase Chronic Myelogenous LeukemiaAccelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous Leukemia+1 more
Incyte Biosciences UK 427
Load More Results